药物干预对多囊卵巢综合征女性人体测量指标的影响：一项随机对照试验的系统评价和荟萃分析
Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
作者信息
Abdalla Mohammed A, Shah Najeeb, Deshmukh Harshal, Sahebkar Amirhossein, Östlundh Linda, Al-Rifai Rami H, Atkin Stephen L, Sathyapalan Thozhukat
机构信息
Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School (HYMS), University of Hull, Hull, UK.
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
出版信息
Clin Endocrinol (Oxf). 2022 Jun;96(6):758-780. doi: 10.1111/cen.14663. Epub 2022 Jan 3.
CONTEXT
Polycystic ovary syndrome (PCOS) is a heterogeneous condition affecting women of reproductive age and is associated with increased body weight.
OBJECTIVE
To review the literature on the effect of different pharmacological interventions on the anthropometric indices in women with PCOS.
DATA SOURCES
We searched PubMed, MEDLINE, Scopus, Embase, Cochrane library, and the Web of Science in April 2020 with an update in PubMed in March 2021.
STUDY SELECTION
The study followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)2020.
DATA EXTRACTION
Reviewers extracted data and assessed the risk of bias using the Cochrane risk of bias tool.
RESULTS
80 RCTs were included in the meta-analysis. Metformin vs placebo showed significant reduction in the mean body weight (MD: -3.13 kg; 95% confidence interval [CI]: -5.33 to -0.93, I² = 5%) and the mean body mass index (BMI) (MD: -0.75 kg/m ; 95% CI: -1.15 to -0.36, I² = 0%). There was a significant reduction in the mean BMI with orlistat versus placebo (MD: -1.33 kg/m²; 95% CI: -2.16 to -0.66, I² = 0.0%), acarbose versus metformin (MD: -1.26 kg/m²; 95% CI: -2.13 to -0.38, I² = 0%), and metformin versus pioglitazone (MD: -0.91 kg/m²; 95% CI: -1.62 to -0.19, I² = 0%). A significant increase in the mean BMI was also observed in pioglitazone versus placebo (MD: + 2.59 kg/m²; 95% CI: 1.78-3.38, I² = 0%) and in rosiglitazone versus metformin (MD: + 0.80 kg/m²; 95% CI: 0.32-1.27, I² = 3%). There was a significant reduction in the mean waist circumference (WC) with metformin versus placebo (MD: -1.21 cm; 95% CI: -3.71 to 1.29, I² = 0%) while a significant increase in the mean WC with pioglitazone versus placebo (MD: + 5.45 cm; 95% CI: 2.18-8.71, I² = 0%).
CONCLUSION
Pharmacological interventions including metformin, sitagliptin, pioglitazone, rosiglitazone orlistat, and acarbose have significant effects on the anthropometric indices in women with PCOS.
背景
多囊卵巢综合征（PCOS）是一种影响育龄女性的异质性疾病，与体重增加有关。
目的
综述不同药物干预对PCOS女性人体测量指标影响的相关文献。
数据来源
我们于2020年4月检索了PubMed、MEDLINE、Scopus、Embase、Cochrane图书馆和Web of Science，并于2021年3月在PubMed上进行了更新。
研究选择
本研究遵循系统评价和Meta分析的首选报告项目（PRISMA）2020。
数据提取
reviewers使用Cochrane偏倚风险工具提取数据并评估偏倚风险。
结果
80项随机对照试验纳入Meta分析。二甲双胍与安慰剂相比，平均体重显著降低（MD：-3.13 kg；95%置信区间[CI]：-5.33至-0.93，I² = 5%），平均体重指数（BMI）显著降低（MD：-0.75 kg/m²；95% CI：-1.15至-0.36，I² = 0%）。奥利司他与安慰剂相比，平均BMI显著降低（MD：-1.33 kg/m²；95% CI：-2.16至-0.66，I² = 0.0%），阿卡波糖与二甲双胍相比（MD：-1.26 kg/m²；95% CI：-2.13至-0.38，I² = 0%），二甲双胍与吡格列酮相比（MD：-0.91 kg/m²；95% CI：-1.62至-0.19，I² = 0%）。吡格列酮与安慰剂相比，平均BMI也显著增加（MD：+2.59 kg/m²；95% CI：1.78 - 3.38，I² = 0%），罗格列酮与二甲双胍相比（MD：+0.80 kg/m²；95% CI：0.32 - 1.27，I² = 3%）。二甲双胍与安慰剂相比，平均腰围（WC）显著降低（MD：-1.21 cm；95% CI：-3.71至1.29，I² = 0%），而吡格列酮与安慰剂相比，平均WC显著增加（MD：+5.45 cm；95% CI：2.18 - 8.71，I² = 0%）。
结论
包括二甲双胍、西他列汀、吡格列酮、罗格列酮、奥利司他和阿卡波糖在内的药物干预对PCOS女性的人体测量指标有显著影响。
Zotero 插件